Strikingly, the administration of the YAP1 activator XMU-MP-1 showcased remarkable efficacy, counteracting these multifaceted events, even in the presence of persistent hyperglycemia and hyperlipidemia in diabetic mice. Here, YAP1 is linked to Hyperglycemia.